SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE
Sera Prognostics Inc. (Nasdaq: SERA) announced the rescheduling of its presentation at the virtual Citi 2022 Healthcare Conference, now set for February 24, 2022, at 9:30 a.m. EST. CEO Gregory C. Critchfield will provide an update and discuss recent achievements. A live webcast will be available on Sera's website, although no replay will be offered. Sera Prognostics is dedicated to enhancing maternal and neonatal health, focusing on early prediction of preterm birth risks through its PreTRM® Test, aimed at enabling proactive interventions.
- CEO Gregory C. Critchfield will discuss recent company achievements at a prominent healthcare conference.
- Sera Prognostics' PreTRM® Test provides early risk assessment for preterm birth, aiding in healthcare delivery improvements.
- The company relies heavily on revenues from the PreTRM test, which represents substantially all revenues to date.
- Potential need for additional capital raises due to net losses and current cash generation challenges.
- High dependence on market acceptance of the PreTRM test amidst concentrated customer base risks.
SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its presentation at the virtual Citi 2022 Healthcare Conference: Services, MedTech, Life Science Tools & HCIT, to be held February 23-24, 2022, has been rescheduled. Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will provide a company update and discuss Sera's latest achievements. Sera's management will also be available for one-on-one meetings with investors.
Citi 2022 Healthcare Conference: Services, MedTech, Life Science Tools & HCIT
Sera's management will participate in a Citi fireside chat on Thursday, February 24, 2022 that has been rescheduled to begin at 9:30 a.m. EST. A live webcast of the company's presentation will be available on the Investors section of the Sera Prognostics website. A webcast replay will not be available.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to deliver early, pivotal information in pregnancy to physicians, enabling them to improve the health of their patients, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is located in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2021 March of Dimes Report Card shows that more than one in ten infants is born prematurely. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately
About the PreTRM® Test
The PreTRM® test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® test permits physicians to identify, during the 19th or 20th week of pregnancy, which women are at increased risk for preterm birth, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® test is ordered by a medical professional.
Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company's planned presentations and one-on-one meetings with investors at the aforementioned investor conference; and the company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; the ongoing COVID-19 pandemic and its impact on our operations, as well as the business or operations of third parties with whom we conduct business; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Final Prospectus on Form S-1, which was filed with the Securities and Exchange Commission on July 14, 2021, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-presentation-rescheduled-for-citi-2022-healthcare-conference-301484306.html
SOURCE Sera Prognostics, Inc.
FAQ
When is the Sera Prognostics presentation at the Citi 2022 Healthcare Conference?
Who is presenting for Sera Prognostics at the conference?
What is the focus of Sera Prognostics?
What is the PreTRM® Test offered by Sera Prognostics?
Will there be a replay of the Sera Prognostics presentation?
